Barbra A. Richardson
Ph.D., University of California, Los Angeles, Biostatistics, 1993.
M.S., University of California, Los Angeles, Biostatistics, 1989.
B.A., Pomona College, Mathematics, 1987.
My main statistical methods research interests are concentrated on developing methods for analysis of infectious disease data and methods for analysis of data with missing values. Recently I worked on developing methodology to estimate breastmilk infectivity among HIV-1 infected mothers, and continue to collaborate on the development of survival analysis methods when the outcome variable is measured with uncertainty.
The majority of my collaborative work has been in HIV-1 prevention studies. I have been involved in studies investigating transmission of HIV-1 through breastfeeding, including serving as lead statistician of a randomized clinical trial to determine the frequency and timing of breastmilk transmission. Additional collaboration on this study has led to analyses determining correlates of genital and breastmilk shedding of HIV-1 DNA, and investigating the effects of breastfeeding on disease progression of HIV-1 infected mothers. I was also involved in a large cohort study with the primary aim of determining whether cytotoxic T lymphocytes in HIV-uninfected exposed infants have a role in protecting against breastmilk transmission of HIV-1. I also was a member of an international working group researching epidemiological, biostatistical, and clinical issues in mother-to-child transmission of HIV-1 (The Ghent Group)
As an investigator at the Statistical Center for HIV/AIDS Research and Prevention (SCHARP) at The Fred Hutchinson Cancer Research Center, I am involved as lead statistician on a variety of studies of microbicides as preventive agents for sexual transmission of HIV-1 - including HPTN 035. In this role I collaborate on protocol teams and provide expertise in study design and other aspects of study development, conduct, and analysis.
I served as the principal investigator (PI) for the statistical coordinating center for the NICHD sponsored HC-HIV study (based at SCHARP). This was a prospective cohort study of over 6,000 women in Thailand, Uganda, and Zimbabwe family planning clinics. The primary aim of the study was to determine if the use of hormonal contraception by HIV-1 uninfected women increases their risk of acquiring HIV-1. I currently serve as the co-PI for the statistical coordinating center for the NIH funded Microbicides Trials Network (MTN).
Lead Statistician for >2 dozen clinical trials and observational studies, 1993-present
Statistical Reviewer, Journal of Infectious Diseases, 1994-2002
Member, HIV Prevention Trials Network STD Working Group, 1999-2000
Member HIV Prevention Trials Network Microbicide Working Group, 2000-2006
Member, Bordeaux International Working Group on Methodology for Trials and Mother-to-Child Transmission of HIV-1, 2000-present
Reviewer, NICHD Review Committee for RFA for a Global Network Research unit for Women's and Children's Health, 2000
Reviewer, XIV International AIDS Conference, 2002
Reviewer, Canadian Institutes of Health Research, 2002
Steering Committee Member, 6th National Symposium of the National Institutes of Health Centers for AIDS Research, 2002
Member, HIV Vaccine Trials Network Safety Monitoring Board, 2003-present
Reviewer, Nestle Foundation, 2003
Advisor, Workshop to discuss data analysis of studies on infant feeding and HIV-transmission and HIV-free survival, World Health Organization, Geneva, Switzerland, November 2003
Reviewer, XV International AIDS Conference, 2004
Chair, Data Safety and Monitoring Board for "Methods for Improving Reproductive Health in Africa" (MIRA) trial, Bill and Melinda Gates Foundation, 2004-2007
Reviewer, NIAID Review Panel for RFP for the DAIDS Virology Quality Assurance Program, March 2005
Reviewer, 3rd IAS Conference on HIV Pathogenesis and Treatment, 2005
Expert Witness, undisclosed case, Round Table Group, 2005-present
Member, Data Safety and Monitoring Board for Theratechnologies Inc. Protocol TH9507/III/LIPO/010, 2005-2007
Member, Data Safety and Monitoring Board for Theratechnologies Inc. Protocol TH9507/III/LIPO/011, 2006-2008
Chair, Data Safety and Monitoring Board for "Contraceptive Effectiveness and Safety Study of the SILCS Diaphragm: the Pivotal Study", CONRAD, 2007-present
Regional Committee Member, WNAR of IBS, 2005-2007
Scientific Reviewer, Bill and Melinda Gates Foundation, 2008
Chair, Data Safety and Monitoring Board for "Sperm suppression and contraceptive protection provided by Norethisterone Enantate (Net-En) combined with Testosterone Undecanoate (TU) in healthy men", CONRAD and WHO, 2008-present
Member, Data Safety and Monitoring Board for "An open-label randomized study of pneumococcal conjugate vaccination in HIV in comparison to polysaccharide vaccine boosting in previously vaccinated patients", Tri-Service AIDS Research Clinical Consortium, NIH, U.S. Military HIV Research Program, 2008.
American Journal of Epidemiology
Expert Review of Anti-infective Therapy
Journal of Acquired Immune Deficiency Syndromes
Journal of the American Medical Association
Journal of Infectious Diseases
Journal of Virological Methods
Journal of Virology
Sexually Transmitted Diseases
Statistics in Medicine
The American Journal of the Medical Sciences
The Lancet Infectious Diseases
(Reading, Writing, Speaking)
Spanish: (Basic, Basic, Basic)
Honors and Awards
2006-2008, Who's Who in Science and Engineering, Marquis
2001, Nominee, Distinguished Graduate Mentor Award, University of Washington
2000, Young Investigator Award, International AIDS Society
1994-1996, Awardee, NIH Post-Doctoral Fellowship in AIDS/STD
1992, Ruth F. Richards Outstanding Student Award, UCLA School of Public Health Alumni Association
1992, Finalist, Society for Clinical Trials Student Scholarship
1989, Elected Member, Iota Chapter of the Delta Omega Society (honorary public health society), UCLA
1987, William Honnold Fellowship for Graduate Study, Pomona College
1987-1992, Traineeship, UCLA, Biostatistics
2004-2009, Joint Associate Member, Fred Hutchinson Cancer Research Center, Public Health Sciences Division, Biostatistics
2003-2009, Research Associate Professor, University of Washington, School of Public Health and Community Medicine, Biostatistics
1996-2003, Research Assistant Professor, University of Washington, School of Public Health and Community Medicine, Biostatistics
1993-1996, NIH Post Doctoral Fellow, University of Washington, Center for AIDS Research, Medicine, Infectious Diseases
1990-1992, Research Assistant, University of California, Los Angeles, Southern California Injury Prevention Research Center
1989-1990, Statistical Consultant, Price Waterhouse, Dispute Analysis and Corporate Recovery Department, Century
1988-1989, Teaching Assistant, University of California, Los Angeles, School of Public Health, Biostatistics
1987-1992, Research Assistant, University of California, Los Angeles, School of Public Health, Biostatistics
1985-1987, Actuarial Student, Milliman & Robertson, Inc.
Age-Disparate Partnerships and Risk of HIV-1 Acquisition among South African Women Participating in the VOICE Trial.. Journal of acquired immune deficiency syndromes (1999).. 2015.
Pharmacological Measures of Adherence and Risk of HIV Acquisition in the VOICE Study.. The Journal of infectious diseases.. 2015.
Soluble Immune Mediators and Vaginal Bacteria Impact Innate Genital Mucosal Antimicrobial Activity in Young Women.. American journal of reproductive immunology (New York, N.Y. : 1989).. 2015.
Levels of Genital Tract Defensins and Cytokines Differ between HIV-Uninfected US and African Women.. American journal of reproductive immunology (New York, N.Y. : 1989).. 2015.
Changes in the contribution of genital tract infections to HIV acquisition among Kenyan high-risk women from 1993 to 2012.. AIDS (London, England). 29(9):1077-85.. 2015.
Tenofovir-based preexposure prophylaxis for HIV infection among African women.. The New England journal of medicine. 372(6):509-18.. 2015.
Passively Acquired Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity in HIV-Infected Infants Is Associated with Reduced Mortality.. Cell host & microbe. 17(4):500-6.. 2015.
A Prospective Cohort Study of the Effect of Depot Medroxyprogesterone Acetate on Detection of Plasma and Cervical HIV-1 in Women Initiating and Continuing Antiretroviral Therapy.. Journal of acquired immune deficiency syndromes (1999).. 2014.
Measles Seropositivity in HIV-Infected Kenyan Children on Antiretroviral Therapy.. The Pediatric infectious disease journal.. 2014.
Elevation of Soluble Intercellular Adhesion Molecule-1 Levels, but Not Angiopoietin 2, in the Plasma of Human Immunodeficiency Virus-Infected African Women with Clinical Kaposi Sarcoma.. The American journal of tropical medicine and hygiene.. 2014.
Systemic Cytokine Levels Show Limited Correlation with Risk of HIV-1 Acquisition.. Journal of acquired immune deficiency syndromes (1999).. 2014.
Antiviral Activity of Genital Tract Secretions following Oral or Topical Tenofovir Pre-exposure Prophylaxis for HIV-1.. Journal of acquired immune deficiency syndromes (1999).. 2014.
Bacterial Vaginosis and the Risk of Trichomonas vaginalis Acquisition Among HIV-1-Negative Women.. Sexually transmitted diseases. 41(2):123-8.. 2014.
Correlates and outcomes of preterm birth, low birth weight, and small for gestational age in HIV-exposed uninfected infants.. BMC pregnancy and childbirth. 14(1):7.. 2014.
Mode of delivery and postpartum HIV-1 disease progression and mortality in a Kenyan cohort.. BMC pregnancy and childbirth. 14(1):257.. 2014.
Toll-like receptor variants are associated with infant HIV-1 acquisition and peak plasma HIV-1 RNA level.. AIDS (London, England). 27(15):2431-9.. 2013.
Incidence and correlates of Chlamydia trachomatis infection in a high-risk cohort of Kenyan women.. Sexually transmitted diseases. 40(3):221-5.. 2013.
Evidence for Efficient Vertical Transfer of Maternal HIV-1 Envelope-Specific Neutralizing Antibodies but No Association of Such Antibodies with Reduced Infant Infection.. Journal of acquired immune deficiency syndromes (1999).. 2013.
A prospective cohort study comparing the effect of single-dose 2 g metronidazole on Trichomonas vaginalis infection in HIV-seropositive versus HIV-seronegative women.. Sexually transmitted diseases. 40(6):499-505.. 2013.